.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,670,537

« Back to Dashboard

Claims for Patent: 5,670,537

Title: Method for effecting tumor regression with a low dose, short infusion taxol regimen
Abstract:Taxol dosages of about 135 mg/m.sup.2 or greater are administered via infusions of less than 6 hours duration; the method makes it possible to provide taxol infusions on an out-patient basis to patients who do not otherwise require hospitalization. In a preferred embodiment, about 135 mg/m.sup.2 of taxol in a cremaphor emulsion is infused over a 3 hour duration, following patient pretreatment with steroids, antihistamines, and H.sub.2 -receptor antagonists sufficient to prevent fatal anaphylactic-like reactions, and preferably sufficient to reduce the occurrence of severe anaphylactic-like reactions in greater than 90% of patients treated. In an alternative embodiment, between 135 mg/m.sup.2 and about 175 mg/m.sup.2 of taxol is provided in a 3-hour infusion, following pretreatment to minimize hypersensitivity responses. A method for rechallenging patients with taxol after episodes of acute hypersensitivity reactions is also disclosed, thus enabling patients to continue taxol therapy who would otherwise be deprived of treatment.
Inventor(s): Canetta; Renzo Mauro (Madison, CT), Eisenhauer; Elizabeth (Kingston, CA), Rozencweig; Marcel (Brandford, CT)
Assignee: Bristol-Meyers Squibb Company (Princeton, NJ)
Application Number:08/715,914
Patent Claims: 1. A method for treating a patient suffering from a taxol-sensitive tumor comprising

(i) premedicating said patient with a medicament that reduces or eliminates hypersensitivity reactions, and

(ii) parenterally administering to said patient about 135-175 mg/m.sup.2 taxol over about three hours.

2. A method for treating a patient suffering from a taxol-sensitive tumor comprising

(i) premedicating said patient with a medicament that reduces or eliminates hypersensitivity reactions; and

(ii) parenterally administering to said patient about 135 mg/m.sup.2 taxol over about three hours.

3. A method for treating a patient suffering from a taxol-sensitive ovarian tumor comprising

(i) premedicating said patient with a medicament that reduces or eliminates hypersensitivity reactions; and

(ii) parenterally administering to said patient about 135-175 mg/m.sup.2 taxol.

4. A method for treating a patient suffering from a taxol-sensitive ovarian tumor comprising

(i) premedicating said patient with a medicament that reduces or eliminates hypersensitivity reactions; and

(ii) parenterally administering to said patient about 135 mg/m.sup.2 taxol over about three hours.

5. A method for treating a cancer patient to effect regression of a taxol-sensitive tumor, said method being associated with reduced hematologic toxicity, said method comprising:

(i) premedicating said patient with a medicament that reduces or eliminates hypersensitivity reactions; and

(ii) parenterally administering to said patient about 135-175 mg/m.sup.2 taxol over about 3 hours.

6. The method of claim 5 wherein the step of premedicating said patient comprises the administration of a medicament selected from the group consisting of steroids, antihistamines, H.sub.2 receptor antagonists, and combinations thereof.

7. The method of claim 6 wherein said taxol-sensitive tumor is an ovarian tumor.

8. A method for treating a cancer patient to effect regression of a taxol-sensitive tumor, said method being associated with reduced hematologic toxicity, said method comprising:

(i) premedicating said patient with a medicament that reduces or eliminates hypersensitivity reactions; and

(ii) parenterally administering to said patient about 135 mg/m.sup.2 taxol over about 3 hours.

9. The method of claim 8 wherein the step of premedicating said patient comprises the administration of a medicament selected from the group consisting of steroids, antihistamines, H.sub.2 receptor antagonists, and combinations thereof.

10. The method of claim 9 wherein said taxol-sensitive tumor is an ovarian tumor.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc